Summary
Background The modest improvement in median survival of advanced non-small-cell lung cancer (NSCLC) by cisplatinbased chemotherapy has led to the current opinion that clinical benefit for the patient is at least as important an end-point as objective response rate (ORR) or survival Clinical benefit response was the primary end-point of this prospective randomised trial in symptomatic, advanced stage I1IB/IV NSCLC, comparing single agent gemcitabine (GEM) to cisplatin-based chemotherapy
Patients and methods Patients received either GEM (1000 mg/m 2 , days 1, 8 and 15) or cisplatin (100 mg/m 2 , day 1) plus Vindesine (3 mg/m 2 , days 1 and 15) (PV), both every four weeks Clinical benefit was measured by a simple metric based on changes in a visual analogue symptom score list, the Karnofsky performance status and the weight Results One hundred sixty-nine patients were randomised (84 GEM, 85 PV) Prognostic factors and baseline symptoms were well balanced between the two arms. Most of the the objective responders and about half of the patients with disease stabilisation experienced clinical benefit Compared to PV, a significantly larger number of GEM-treated patients experienced a clinical benefit (48 1 vs 28 9%, P = 0 03) that lasted significantly longer (median duration 16 vs 10 weeks, P -0 01) No important differences in ORR, time-to-progression or median survival were observed Grade 3+4 toxicily was significantly higher in the PV-group for leukopenia (P = 0 0003), neutropenia (f < 0.0001), nausea/vomiting (P = 0 0006), alopecia (P < 0 0001), and neurotoxicity {P = 0 04) Some severe pulmonary toxicity to GEM was noted.
Conclusion Comparison of GEM with cisplatin-based therapy in symptomatic, advanced NSCLC demonstrates that GEM produces significantly a stronger and longer-lasting clinical benefit, probably due to its equal effectiveness in terms of ORR, time-to-progression or survival, combined with significantly less severe therapy-related toxicity
Introduction
Several well-designed studies and meta-analyses have convincingly demonstrated that cisplatin-based chemotherapy improves median survival of advanced nonsmall-cell lung cancer (NSCLC) patients, compared to best supportive care alone [1] [2] [3] [4] The therapy is not curative, and the improvement in median survival by cisplatin-based chemotherapy was only six to eight weeks in a large meta-analysis [4] Despite the merits of cisplatin, its toxicity remains a matter of concern in metastatic NSCLC, since improvements in supportive care have not solved the issues of delayed emesis, renal toxicity and cumulative neuropathy. This has led to the current opinion that clinical-benefit for the patient is at least as important and end-point as the objective response rate (ORR) or survival.
New drugs, amongst others gemcitabine, have shed new light on this dilemma. In non-controlled phase II studies, single agent gemcitabine (GEM) showed an ORR of 20 to 22%, with mild reversible toxicity, and a survival rate similar to that seen with cisplatin-based chemotherapy [5] [6] [7] . This result suggested that treatment with GEM might improve the clinical benefit for the metastatic patient, because the advantage of the activity is not so strongly counteracted by toxicity. In one of the non-controlled phase II studies, it was reported that GEM improved disease-related symptoms in 70% of the patients and increased the performance status in 44% [5] .
Two randomised phase II trials have compared cisplatin-based chemotherapy with GEM in advanced NSCLC [8, 9] . Both of these studies, however, have concentrated on the classical end-points of ORR, toxicity, and survival.
This prospective, randomised, phase III comparator study was initiated in 1996 to examine the clinical benefit response rate as a primary end-point The study question was whether a treatment with GEM, compared to cisplatin-based chemotherapy, would result in a better clinical benefit for patients with symptomatic, advanced NSCLC. The control treatment was cisplatin plus a vinca-alkaloid, one of the cisplatin-based regimens commonly used in many European countries at that time. When used in randomised phase III studies, this schedule has response rates ranging from 19% to 33% and median survival times ranging from 6 to 12 months [10] [11] [12] [13] [14] The primary end-point was to be measured by a clinical-benefit metric, based on patient-assessed disease related symptoms, clinician-assessed Karnofsky performance status (KPS), and weight change. Secondary endpoints were the ORR, the time-to-response, the duration of response, the time-to-progression, the survival, and the hematologic and non-hematologic toxicity.
Informed consent
Written informed consent was obtained in all patients The informed consent document was reviewed by the ethical review committee in all participating centres The study was conducted in accordance with Good Clinical Practice guidelines and the Helsinki Declaration
Randomisation procedure
Patients had to be able to score their symptoms on a VAS in a consistent manner during a lead-in penod of one week (see below) After this, and after a thorough eligibility check, randomisation between a treatment with GEM or PV was carried out by fax at a central location for all sites Randomisation was performed according to the CONSORT guidelines [16] Each patient's study drug regimen was unknown until the time of randomisation Randomisation was stratified on four baseline characteristics disease related symptoms (three strata low, 1 e , between 20 and 60, moderate, l e , between 60 and 300, and high, 1 e , above 300), KPS (two strata 80-100 or 60-70), disease stage (two strata IIIB or IV), and lnvestigational site. Imbalance with respect to treatment arm in each stratum for each characteristic was avoided by using the algorithm outlined in Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial by Pocock and Simon [17] , with the randomisation probability parameter set at P = 0 75
Treatment schedule GEM-treatment gemcitabine 1000 mg/m 2 intravenously for 30 minutes was given on days 1, 8, and 15 of a 28-day cycle without standard use of anti-emetics (after the first cycle prophylactic non 5-HT3-antagonist anti-emetics were allowed at the discretion of the investigator)
PV-treatment cisplatin 100 mg/m 2 in 500 ml of glucosahne was given as a one-to four-hour infusion on day 1 of each 28-day cycle with standard prehydration, forced diuresis, and use of 5-HT3-antagonists Vindesine was administered at 3 mg/m 2 (maximum 5 mg) on days 1 and 15 of the same 28-day cycle
The body surface area of the patient was calculated according to the actual height and weight at the start of each cycle
Patients and methods

Eligibility criteria
Patients were eligible if they had a histologic or cytological diagnosis of NSCLC, stage 1MB (not amenable to surgery or radiation of curative intent) or stage IV, according to the American Joint Committee on Cancer staging [15] At least one bi-dimensionally measurable target lesion had to be present No prior chemotherapy or immunotherapy were allowed, while prior radiation therapy was allowed as long as the irradiated area was not the only source of measurable disease
The KPS had to be >60% and the life expectancy 5=3 months Patients had to be symptomatic, defined as having a visual analogue score (VAS) of at least 20/100 for at least 1 symptom (see below)
Adequate bone marrow reserve (granulocytes > 1 5 x IO 9 /1, platelets > 100 x 10 9 /l), adequate renal function (calculated or measured creatinine clearance ^60 ml/min) and hepatic function (bilirubin < 1 5 times normal, prothrombin time < I 5 times control, transaminases (ALT and AST) <3 times normal, <5 in case of patients with known metastatic liver disease) were required Active infection, symptomatic central nervous system metastases, serious concomitant systemic disorders incompatible with the study, history of a previous or current second primary malignancy (except m situ carcinoma of the cervix or adequately treated basal-cell carcinoma of the skin) and use of any lnvestigational agent in the month before enrolment were criteria for exclusion Dose modifications and toxicity Dose adjustments were based on the hematologic counts (leukocytes, granulocytes, platelets), serum chemistry including creatinine obtained prior to each cycle, and ongoing clinical assessment of non-hematologic toxicities Toxicity was scored according to the World Health Organisation (WHO) toxicity scale [18] All patients who received at least one dose of GEM or PV were evaluated for toxicity
The day 1 dose of a subsequent cycle was administered if leukocytes were 5=4 0 x 10 9 /l and platelets 5t 100 x 10 9 /l If the leukocytes were below 4 0 x 1O 9 /1, granulocytes had to be > 1 5 x 10 9 /l If these criteria were not met, the cycle was delayed for one week If therapy could not be administered for six weeks from day 1 of the previous cycle, the patient was discontinued from the study Patients who sustained either febrile neutropenia, WHO grade 4 thrombocytopenia, or bleeding associated with thrombocytopenia were to be dosed at 50% of the commencing dose of the previous cycle Subsequent dose escalation to the original dose was allowed, provided that the patient tolerated the doses given at the 50% level On days 8 and 15, full dose Gemcitabine was given if granulocytes were Ss 1 5 x 10 9 /l and platelets 5* 100 x 10 9 /l A 25% dose reduction was used in cses involving WHO grade 2 granulocytopenia or thrombocytopenia A 50% dose reduction was used in cases of grade 3 granulocytopenia or thrombocytopenia The dose was omitted in when there were lower blood counts On day 15, full dose Vindesine was given if granulocytes were > 1 5 x 0 9 /l and platelets > 100 x 10 9 /l A 50% dose reduction was used when granulocytes were between 1 5 and 1 0 or platelets between 100 and 75 The dose was omitted in case of lower blood counts On day 1, cisplatin was reduced to 75% of the planned dose if the creatinine clearance was between 40 and 60 ml/min Cisplatin was stopped if the clearance fell below this level
The administration of the day 1 dose of a subsequent cycle also required that other non-haematological toxicmes (except alopecia) had to be below WHO grade 3
Duration of treatment
Therapy was continued until disease progression or unacceptable toxicity, and up to six cycles of PV, or up to eight cycles of GEM (because of the lower cumulative toxicity expected with this agent) Other possible reasons for discontinuation were patient request, pregnancy, or when the attending physician thought a change of therapy would be in the best interest of the patient Second-line treatment was not a common practice in Belgium during the study interval, mainly due to the lack of reimbursement for new active drugs against NSCLC The administration of second-line chemotherapy was left to the discretion of the co-investigators, but was to be listed in the patients' records
Criteria for response
Response was assessed every two cycles, according to the WHO criteria, the standard system during the study period [19] Responses had to be confirmed after a minimum of four weeks and a maximum of eight weeks Intent-to-treat analysis was used all patients who were not or could not be fully evaluated were considered to be treatment failures All patients with early progression, early tumour-related death and tumour increase after two cycles were considered to have progressive disease
All claimed responses and stable diseases were to be reviewed by a panel including at least two oncologists (never reviewing their own patients), one research nurse, and one independent external radiologist blinded to treatment
Time parameters
Time-to-response was defined as the interval between randomisation and the first evaluation indicating a response Response duration was defined as the time from achievement of objective response until disease progression Time-to-progression was defined as the interval between randomisation and the first documentation of disease progression Survival was defined as the interval between randomisation and death, or date of the last contact for censored patients
Evaluation of clinical benefit
The primary endpoint was a clinical-benefit response This was a dichotomous variable, as each patient was classified as a clinicalbenefit responder or non-responder on the basis of a clinical-benefit metric adapted from pancreatic cancer studies with gemcitabine (Table I) [20] This metric is based on 2 primary measures of clinicalbenefit (change in lung cancer disease related symptoms and change in KPS) and one secondary measure of clinical benefit (change in weight) Each of a patient's primary clinical-benefit measures (lung cancer symptoms and KPS) was categorised as positive, stable, or negative (see details below) The secondary clinical-benefit measure (weight change) was categorised as either positive or negative A patient was defined to be a clinical-benefit responder if one primary measure was positive and one was stable, or if both primary measures were positive As soon as one primary measure was negative, the patient was considered to be a non-responder If both primary measures were stable, the change in weight was used to determine the clinical-benefit outcome The questionnaire was not a quality-of-hfe instrument, but rather a symptom-specific questionnaire for lung cancer, consisting of six symptoms scored on a visual analogue scale ranging from 0 to 100 dyspnea, cough, hemoptysis, fatigue, anorexia and pain The use of a VAS to rate lung cancer symptoms was described previously [21] In our study, the sum of the measures expressed the overall symptom seventy, thus with a maximum symptom score of 600 Before enrolment, during a stabilisation lead-in period, the patient scored his symptoms daily for one week This stabilisation lead-in period was meant to check the ability of the patient to score his symptoms consistently, and served as the baseline value from which changes in symptom-related variables were measured The baseline measurement of disease symptom intensity was the mean of the disease symptom intensity score on the day of randomisation and the scores from the two previous days before randomisation After randomisation, each patient recorded his symptom intensity on a weekly patient diary card On the days of chemotherapy administration, the patient made the symptom score before the visit, and the symptom scores of the previous period were collected at the visit (patients were not able to compare with their previous scores) Symptom improvement was defined as an improvement in the mean overall symptom score by at least 30 mm, sustained for at least two cycles
The KPS was evaluated by the clinician at baseline and every two weeks during the study Performance status improvement was defined as an improvement of the mean of the KPS scores by at least 5%, sustained for at least two cycles The patient's weight (in light dress, without shoes, using a consistent scale) was recorded once at baseline, and every two weeks during the study
The time to worsening of clinical status was defined as the interval from the date of randomisation until the first evidence of worsening in the post baseline clinical-benefit assessment
Statistics
We calculated that a study with ± 80 evaluable patients in each arm would be able to test the hypothesis of a clinical-benefit response rate of 25% in the control arm and 46% in the new arm with 80% power and 0 05 type I error It was assumed that 20% of the randomised patients would not qualify for clinical-benefit analysis Therefore, 100 patients in each arm were needed
The predefined maximum duration of the study was three years, with no planned interim analysis Numeric values were expressed as mean ± standard deviation (SD) Response rate and the difference in response rate between treatment groups were determined with 95% confidence intervals (95% CI)
Comparisons between groups were based on the chi-square statistic (or the Fisher's exact test in case of cells with numbers below 5) for nominal variables, or on a r-test for continuous variables Time-to-event parameters were calculated by a Kaplan-Meier analysis, and the long-rank statistic was used for comparison of the groups [22] 169 patients enrolled To ensure accurate, complete, and reliable data, a start-up training session to instruct the investigators was held in each centre Periodic visits to each centre, with monitoring of original source documents and clinical report forms, were carried out during the entire study period Study-site personnel was available at all times for consultation by mail, telephone, and/or fax The clinical report data were reviewed and evaluated by computer edits to detect errors in data collection
Results
Patients
During the maximum inclusion period of three years, between May 1996 and April 1999, a total of 169 patients were randomised (84 GEM, 85 PV, Figure 1) .
The baseline characteristics of the patients are presented in Table 2 There was an equal distribution over the two arms for age (mean 63 7 for GEM vs 63.1 for PV, P = 0 64) and for sex (82.1% males for GEM vs. 83 5% for PV, P = 0.81) In both arms, the majority of the patients had stage IV disease, 69% of the GEM-patients versus 67% of the PV-patients (P = 0.78) The baseline KPS was between 80 and 100 in 56 GEM-patients and 55 PV-patients. It was between 60 or 70 in 27 GEMpatients and 28 PV-patients. (P = 0.83) The baseline symptom score was also comparable in both arms (P -0.33).
Treatment administration
A total number of 271 GEM-cycles was administered in 84 patients For PV, this was 236 cycles in 82 patients. The mean number of cycles in the GEM-arm was 3.2 (SD 2.2), in the PV-arm 2 8 (SD 1.6).
In the GEM-arm, 99.6% of the planned day 1 doses could be delivered, 92.4% of the planned day 8 doses, and 91.6% of the planned day 15 doses There were 11.4% reductions and 3.3% omissions of the dose on day 8 For 0 Including progressive disease after two cycles, early progression and early tumour-related death day 15, this was 12.6% and 3.7%. In the PV-arm, 98.3% of the planned cisplatin doses could be delivered, 98.7% of the planned day 1 Vindesine doses, and 71.8% of the planned day 15 vindesine doses. There were 7.2% reductions and 24.6% omissions of the day 15 vindesine dose.
The reasons for protocol discontinuation were disease progression (including early progression and early tumour-related death) in 114 patients (60 GEM, 54 PV), investigator decision based on toxicity in 18 patients (7 GEM, 11 PV), patient decision in 14 (5 GEM, 9 PV), protocol completion in 15 patients (9 GEM, 6 PV), a non-drug-related serious adverse event in 7 patients (3 GEM, 4 PV), and a refusal to start after randomisation in 1 patient. Consequently, only about 10% of the patients could complete their treatment.
Second-line treatment was administered in 23 individuals of the GEM-group and 18 of the PV-group. It was deemed effective by the investigator in three patients of the GEM-arm and in only one of the PV-arm.
Response
Sixteen patients (six GEM, ten PV) were not evaluable for response (Table 3) . One patient chose not to start therapy after being randomised to PV. Six patients (two GEM, four PV) preferred to stop treatment before response assessment after two cycles, because of nausea and vomiting. In five patients (three GEM, two PV), the investigator decided on an early discontinuation of chemotherapy because of toxicity (details below). Finally, four patients experienced a non drug-related serious adverse event (one gastric bleeding, one sepsis, two pulmonary embolus) before response assessment after two cycles. The radiological data for 93% of the patients reported by the investigator to have response or stable disease could be reviewed, the other data could no longer be retrieved. Six investigator-reported responses and five stable diseases were not retained.
The intent-to-treat overall response rate was 20.2% in the 84 GEM patients (95% CI: 11.4-29.0) and 20.0% in the PV patients (95% CI. 11.2-28.8).
Time parameters
These are summarised in Table 4 There were no significant differences between the two groups in terms of median time-to-response (P = 0.72), median duration of response (P = 0.22), and time-to-progression (P = 0.55).
The survival was slightly better for the GEM treated Figure 2 ) and the evaluable group, although the differences were not significant The relative death risk in the total number of GEM-patients compared to the PV-patients was 0.787 (95% CI 0 573-1.081, P = 0.14).
Clinical-benefit analysis
The clinical-benefit response parameters are listed in Table 5 Twenty-seven of the 34 patients (79.4%) with an objective response experienced a clinical benefit, with a median duration of more than 40 weeks This was significantly better than the group with stable disease, where the clinical-benefit response was 22 of 44 (50%), with a median duration of 24 weeks (P = 0.007). It was very significantly better than the group with progression, where clinical-benefit response was rare and short (P < 0.0001). Cisplatin-vindesine (n = 76) "P < 005, h P < 001, C P < 0001 The difference in clinical benefit between the two treatment arms is illustrated in the lower part of Table 5 and in Figure 3 It was found that a substantially larger number of GEM-treated patients experienced a clinical benefit (48.1% vs 28.9%, P = 0.03). The median duration of this clinical benefit was also longer lasting in the GEM-group (median 16 weeks) compared to the PVgroup (median 10 weeks, P = 0.01).
In a subgroup analysis, it was found that in both treatment arms the majority of the patients with an ORR had a clinical benefit (14 of 17 GEM-responders, 13 of 17 PV-responders). The difference between the two treatments was most obvious in the patients with disease stabilisation. 15 out of 24 GEM-patients with stable disease enjoyed a clinical benefit, while this was only present in 7 of 21 PV-patients (P -0.05).
Toxicity
The grade 3+4 hematologic toxicity, expressed per cycle and per patient, is depicted in Table 6 .
Grade 3 + 4 leukopenia was significantly more frequent in the PV-arm, both per cycle (P = 0.0003) and per patient (P = 0.02) This was also the case for neutropenia, with a P < 0.0001 in the analysis per cycle, and a P = 0.003 in the analysis per patient The occurrence of severe anaemia or severe thrombocytopenia was rare in both treatment arms.
The total (grades 1 to 4) and the grade 3 + 4 nonhematologic toxicity, expressed as the worst toxicity per patient, is shown in Table 7 . Only the items present in more than 5% of the patients in one of the treatment arms are listed in the table.
There was a significantly higher occurrence in the PV-arm of nausea/vomiting (P = 0 0006), hair loss (P < 0.0001), and neurotoxicity (P = 0.04). This was also the case when severe toxicity was analysed: more grade 3 + 4 nausea/vomiting (P = 0.0002), hair loss (P = 0 04), and neurotoxicity (P = 0.03).
On the other hand, disturbance of cytolytic (P < 0.0001) and cholestatic (P = 0.04) liver function tests, occurrence of proteinuria (P = 0.04), mucositis (P = 0.02), pulmonary symptoms (P -0.0005), fever (P = 0.05), allergy (P = 0.05), and cutaneous side-effects (P -0.001) were more frequent in the GEM-arm. This was mostly due to a higher frequency of grade 1 + 2 toxicity. It should be noted, however, that there were four instances of grade 3+4 pulmonary toxicity and two instances of grade 3+4 allergy in the GEM-arm Toxicities occurring in less than 5% of the patients were six cases of grade 1 + 2 cardiac rhythm disturbances (3 GEM, 3 PV), one GEM-patient with grade 1 cardiac dysfunction, five instances of grade 1 + 2 altered consciousness (4 GEM, 1 PV), and one PV-patient with grade 2 hearing loss. One GEM-patient developed a haemolytic uremic syndrome [23] . Toxicity was the reason for treatment discontinuation by the investigator in 17 patients In 11 PV-patients, this was due to nausea/vomiting in four, neuropathy in four, deterioration of the general condition in two, and nausea/vomiting combined with neuropathy in one. Six GEM-patients went off protocol for reasons of toxicity two for pulmonary symptoms (one acute respiratory distress syndrome (ARDS), one bronchospasm), two for allergy, one for toxic hepatitis [24] , and one for haemolytic uremic syndrome [23] . Drug toxicity was considered by the investigator to be the cause of death in two GEM-patients (one ARDS, one toxic hepatitis)
Discussion
In this prospective randomised phase III comparator study, we were able to show that GEM, compared to cisplatin-based chemotherapy, resulted in a significantly longer clinical benefit in a significantly larger proportion of patients with symptomatic, advanced NSCLC. Although the study was not designed nor powered to detect small differences in the secondary end-points, such as objective response rate or survival, there were no major differences across arms in these results GEM treatment was characterised by significantly less grade 3 and 4 therapy-related toxicity.
The novel approach of evaluating clinical benefit in NSCLC does not have the ambition of a true multidimensional quahty-of-life instrument, but it has the potential to avoid the sometimes laborious collection and analysis of valid quahty-of-life data in multi-centre studies. It was chosen as primary end-point of this study, and it could be analysed in 77 GEM and 76 PV patients. Therefore, the power of the study was slightly less than originally planned (77% instead of 80%). The collection of the data for clinical-benefit measurement proved to be quite feasible in the multi-centre setting of this trial: 85.2% of the performance scale items required by the protocol were collected, 82.5% of the patients' symptom scores, and 83.4% of the weight measurements. On the other hand, clinical-benefit measures more than just symptom control. This instrument is based on the combination of 3 simple, but important, patient assessments in daily clinical practice, symptoms, performance status and weight. Symptom control is of obvious importance for the patient. The important role of performance status [25] and of weight [26] in lung cancer are well known. When we designed this trial, the concept of clinical benefit was already in use in a GEM pancreatic cancer multi-centre study, co-ordinated by H. Burris from San Antonio. The initial results at that time indicated that, although the objectively measurable response rate in pancreatic cancer was low, there was evidence of clinical benefit in a larger number of patients, characterised by disease symptom relief with decrease in analgesic requirements, improved performance status, and weight gain.
The validity of this clinical-benefit metric for comparing different treatments in NSCLC now gains further credibility by the consistent data analysis of the clinical benefit according to ORR. The majority of the objective responders experienced a clinical benefit, which was also present in about half of the patients with stable disease, and very rare in progressive tumours.
Using this concept, GEM, compared to PV, resulted in a significantly longer-lasting clinical benefit in a significantly larger proportion of patients. The median duration of clinical benefit in the GEM-arm of this randomised trial (16 weeks) is in line with the data from the non-controlled phase II study of Gatzemeier et al. [7] In that trial, the median duration of improvement in performance status was 18 weeks, and the median duration of symptom improvement 11 to 13 weeks Our data also correspond with the findings of Anderson et al, who reported a symptomatic response rate higher than the ORR when advanced NSCLC patients were treated with GEM [5] . In our randomised comparison, the difference in clinical benefit between the two arms proved to result mainly from a difference in the patients with disease stabilisation. Objectively responding patients fared better in both arms, but the clinicalbenefit response rate was significantly higher when stable disease was reached by GEM instead of PV. The finding of a more frequent and longer-lasting clinical benefit in the GEM-arm versus the PV-arm can probably be understood by the combination of at least equipotent activity and substantially less toxicity.
Clinical benefit as determined in our study relies in part on assessment of KPS, which is determined by the investigators Since these could not be blinded to the therapy allocation of the patient, one might suggest that (unintentional) investigator bias may have played a role in the study outcome If this would have been the case, a large proportion of the GEM-patients experiencing clinical benefit would have been so categorised based on improved K.PS alone, but with stable symptoms and weight. This could be ruled out, since the majority of those experiencing a clinical benefit in both arms was based on improvement of patients' symptom scores, and only in few cases on KPS alone (five in the GEM-arm, four in the PV-arm).
Two other, smaller, phase II randomised, studies comparing the ORR and survival of GEM versus cisplatin-etoposide (PE) have been reported [8, 9] . In a study of 53 patients, Perng et al [8] reported 5 responses in 26 evaluable patients in the GEM-arm (19.2%) versus 5 responses in 24 evaluable patients in the PE-arm (20 8%). The median survival time was 9.2 months in the GEM-arm veisus 12 months in the PE-arm (P = 0.65) In the study by Manegold et al.
[9], 12 of 66 evaluable GEM-patients had a response (18.2%) versus II of 72 evaluable PE-patients (15.3%). Median survival times were similar. 6.6 months for GEM and 7.6 months for PE (P = 0.9). Our data confirm the equivalent objective response and treatment outcome findings, but are with an intent-to-treat analysis and in a larger phase III multi-centre context.The phase III context, together with the selection of symptomatic patients, probably also explains why the median survival in both arms of our study is somewhat lower than the median survival in the phase II non-controlled studies.
In our study, severe grade 3 or 4 therapy-related hematologic toxicity in the GEM-arm was low: 0 7% for anaemia, 1.9% for leukopenia, 6.5% for neutropenia, and 1.1% for thrombocytopenia This is in accordance with the detailed phase II toxicity data, except for neutropenia which occurred in up to 25.3% of the patients in one trial [7] This could be explained by a more strict hematologic toxicity monitoring in a phase II setting, and by the fact that a higher dose of 1250 mg/m 2 was administered in that study.
Both severe and overall non-hematologic toxicity was significantly lower in the GEM-arm for nausea/vomiting, alopecia and neurotoxicity. The somewhat high occurrence of nausea/vomiting in the PV-arm could be in part related to the schedule used to control emesis, which consisted of 5-HT3-antagonists, but not corticosteroids. This choice was made, however, because administration of a high dose of corticosteroids in one arm only might influence clinical-benefit comparison across arms.
About twice as many PV-patients discontinued treatment for toxicity reasons. The investigator decided to stop chemotherapy in 11 PV-patients (vs. 6 GEM-patients), while the patient decided to stop PV therapy in 9 instances (vs 5 for GEM). Perng et al.
[8] also reported a lower occurrence of nausea/vomiting in the GEMarm. Manegold et al.
[9] noted substantially decreased nausea/vomiting and hair loss.
There was a higher occurrence of fever (including flulike syndrome), proteinuna, liver function test disturbances, allergy, cutaneous and pulmonary abnormalities in the GEM-arm. Most of these toxicities have been described in the previous phase II trials [5, 6] . They were of grade 1 or 2 only, reversible, non-progressive, and did not lead to treatment discontinuation.
A few cases of more severe, but rare, toxicity experienced by patients in this trial were described elsewhere (haemolytic uremic syndrome [23] and cholestatic liver failure [24] ). These toxicities were also noted by others [6, 27, 28] .
Side effects such as oedema, rash and transient dyspnea in the absence of cardiac dysfunction are well known since their description in previous phase II studies [5] [6] [7] . They usually are transient and mild. The pathogenesis has not been solved completely. In some instances, the side effects have been ascribed to a vasculitic effect with possible capillary leak syndrome [5] , in analogy with the more common occurrence of capillary leak syndrome associated with the use of cytosine arabinoside, an older deoxycytidine analogue with structural similarity to GEM [29] Dyspnea can occur in up to 10% of the patients, usually within hours following Gemcitabine injection, is mild, short-lived, usually abates without any specific therapy, and leads to treatment discontinuation in only 0.6% of the cases [30] . Therefore, the four instances of grade 3 or 4 pulmonary toxicity and two cases of grade 3 or 4 allergy in the GEM-arm of this study need to be detailed. One patient was rated with a grade 4 pulmonary toxicity He developed a fatal ARDS (non-cardiogenic pulmonary oedema) after the third administration of GEM in the first cycle. Another patient developed dyspnea with hypoxaemia and interstitial infiltrates with ground-glass opacities on highresolution CT of the thorax at the start of the fourth cycle of GEM There were no arguments for cardiac dysfunction, infection or carcinomatous lymphangitis The dyspnea improved after treatment with corticosteroids, and the chemotherapy was changed into PV. The phenomenon of possibly fatal ARDS also has been described by others [31] . Two patients in our study were coded with a grade 3 pulmonary toxicity and allergy. One of them developed bronchospasm with increasing severity despite corticosteroid prophylaxis, and treatment had to be discontinued after four cycles. The other patient developed fever, oedema and bronchospasm, and treatment was stopped after three cycles Both patients recovered.
In conclusion, we were able to measure a clinicalbenefit response in NSCLC with the metric previously described in pancreatic cancer, and this apparently interesting tool for multi-centre studies merits further study.
We found that single agent GEM is a better choice than PV in terms of clinical benefit, when a palliative treatment for patients with symptomatic, advanced NSCLC is sought. We think this finding adds valuable information to the discussion of whether Cisplatin is still mandatory in patients with advanced NSCLC [32] . The finding can also be correlated with the interesting findings of Anderson et al., comparing GEM plus best supportive care (BST) versus BST alone [33] That study also had patient well-being, expressed by a 14-item symptom score list, as primary end-point, and demonstrated that symptom improvement was significantly better in the GEM plus BST arm Together with our data, this study suggests that single-agent GEM is a good treatment option for patients with a high symptom burden, with poorer performance status, or with higher age.
In our view, further study on this type of patient should address the question whether the use of GEM combined with new active drugs with mild non-hematologic toxicity, such as docetaxel, pachtaxel or vinorelbine, could yield even superior clinical benefit than single agent GEM can.
